GlassScriptPhysician profile
Barbara A Gurden
NPI 1063465631
$3,792.71
in general payments reported to CMS, 2019-2025
28 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.83 · 2020: $11.87 · 2021: $87.12 · 2022: $330 · 2023: $1,173 · 2024: $1,113 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,338.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,183.00 | 2021-2025 | |
| Novo Nordisk INC | $824.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $267.22 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $253.51 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $153.30 | 2024-2025 | Caplyta |
| Mylan Specialty L.P. | $145.84 | 2022-2024 | Yupelri |
| Pfizer INC. | $107.91 | 2024-2025 | |
| Exact Sciences Corporation | $102.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $75.84 | 2022-2023 | Freestyle Libre 3 |
| Phadia US INC. | $73.51 | 2022-2023 | Immunocap |
| Bayer Healthcare Pharmaceuticals INC. | $71.43 | 2022-2025 | |
| Glaxosmithkline, LLC. | $65.35 | 2024 | Trelegy Ellipta, Arexvy |
| Myriad Women'S Health, INC. | $58.16 | 2023 | Myrisk |
| Otsuka America Pharmaceutical, INC. | $56.18 | 2025 | Rexulti |
| Alkermes, INC. | $49.32 | 2023-2024 | Vivitrol, Vivitrol |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $41.70 | 2023 | Otezla, Repatha |
| Boston Scientific Corporation | $36.02 | 2023 | |
| Axsome Therapeutics, INC. | $33.55 | 2025 | Auvelity |
| Verona Pharma, INC. | $29.36 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $28.69 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.62 | 2025 | Keveyis |
| Gilead Sciences, INC. | $21.85 | 2025 | |
| Inspire Medical Systems, INC. | $19.31 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $18.96 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $15.00 | 2025 | Zoryve |
| Esperion Therapeutics, INC. | $14.37 | 2025 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $11.49 | 2019 | |
| Endogastric Solutions, INC | $9.73 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Gurden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.